Triptans | |
---|---|
Drug class | |
![]() Chemical structure of sumatriptan, the prototypical triptan | |
Class identifiers | |
Use | Migraine, cluster headache |
ATC code | N02CC |
Biological target | Serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptors |
Legal status | |
In Wikidata |
Triptans are a family of antimigraine drugs used to abort migraines and cluster headaches.[1] While effective at treating individual headaches, they do not provide preventive treatment and are not curative. They are not effective for the treatment of tension–type headache,[2] except in persons who also experience migraines.[3] Triptans do not relieve other kinds of pain. They are taken orally and by other routes.
The drugs of this class act as agonists for serotonin 5-HT1B and 5-HT1D receptors at blood vessels and nerve endings in the brain. Some also activate the 5-HT1F receptor. Structurally, triptans are substituted tryptamines or closely related to tryptamines.
The first clinically available triptan was sumatriptan, which has been marketed since 1991. Subsequently, a variety of other triptans have also been marketed, including zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. Triptans have largely replaced ergoline drugs like ergotamine and dihydroergotamine, an older class of medications used to relieve migraine and cluster headaches.[4]